Bevacizumab for the management of diabetic macular edema

Francisco Rosa Stefanini, J Fernando Arevalo, Mauricio Maia

Objectives: To summarize the studies examining bevacizumab for the management of diabetic macular edema (DME), focusing on the efficacy and duration of the clinical benefits of decreasing DME and the improvement of best-corrected visual acuity (BCVA). There is strong evidence that intravitreal bevacizumab injection therapy has a good cost-effective profile in the management of DME and may be associated with laser photoocoagulation; however, its clinical superiority in terms of the duration of DME regression and the improvement of BCVA compared with intravitreal ranibizumab and other intravitreal anti-VEGF therapies remains unclear and deserves further investigation.

INTRODUCTION

Diabetic retinopathy (DR) is a leading cause of vision loss in working-age population and is related to 1%-5% of cases of blindness worldwide. Diabetic macular edema (DME) is the most frequent cause of DR vision loss and is an important public health problem. Recent studies have implicated vascular endothelial growth factor (VEGF) in DR and DME pathogenesis, as well as provided evidence of the benefits of anti-VEGF agents for the management of such conditions. Despite the benefits of intravitreal ranibizumab injection for the management of DME, the cost-effectiveness of intravitreal bevacizumab therapy has gained increasing interest in the scientific community. This review summarizes the studies examining bevacizumab for the management of DME, focusing on the efficacy and duration of the clinical benefits of decreasing DME and the improvement of best-corrected visual acuity.

Bevacizumab for the management of diabetic macular edema

© 2013 Baishideng. All rights reserved.

Key words: Diabetic macular edema; Bevacizumab; Anti-vascular endothelial growth factor; Diabetic retinopathy

Core tip: This review summarizes the studies examining bevacizumab for the management of diabetic macular edema (DME), focusing on the efficacy and duration of the clinical benefits of decreasing DME and the improvement of best-corrected visual acuity.

Stefanini FR, Arevalo JF, Maia M. Bevacizumab for the management of diabetic macular edema. World J Diabetes 2013; 4(2): 19-26 Available from: URL: http://www.wjgnet.com/1948-9358/full/v4/i2/19.htm DOI: http://dx.doi.org/10.4239/wjd.v4.i2.19
from microaneurysms and dilated retinal capillaries with abnormal permeability. Complete or partial rings, as a circinate pattern of hard exudates, often demarcate the macular edema\(^8\) (Figure 2A). In diffuse macular edema, generalized leakage from dilated capillaries is observed throughout the posterior pole (Figure 2B). Occlusion of a portion of the capillary bed causes dilation of the patent capillaries, which tend to leak, leading to edema\(^9\). The risk factors associated with diffuse macular edema are systemic hypertension, adult-onset diabetes mellitus and poor blood glucose control, cardiovascular disease, impaired renal function, increased number of retinal microaneurysms, advanced retinopathy and vitreomacular traction\(^9,10\). It is estimated that DME occurs in 3% to 6% of all patients with diabetes aged 18 or older\(^11\). A large epidemiological study indicated that macular edema was present in 26% of the study patients with DR\(^12\).

The most efficient tool for preventing vision loss from DR is screening and identification of at-risk patients, along with regular office visits to educate patients on the importance of tight blood sugar and blood pressure control in both type 1 and type 2 diabetes\(^3\).

Once a patient develops DME, the gold standard treatment in recent decades has been macular photocoagulation (MPC) using the laser technique, which reduces the risk of moderate visual loss by approximately 50% (Figure 3)\(^13\). A review of the data from the Early Treatment DR Study (ETDRS) demonstrated that approximately 40% of the patients who demonstrated improvement with focal laser treatment and a baseline best-corrected visual acuity (BCVA) worse than 20/40 had gained 6 or more letters at 3-year post follow-up\(^13,14\). Recently, the Diabetic Retinopathy Clinical Research Network (DRCR.net) has demonstrated BCVA improvement of more than 5 letters of vision in 51%, 47% and 62% of eyes treated with MPC after 1, 2 and 3 years of follow-up, respectively\(^5,15-17\).

VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS AND DME

In recent years, alternative or adjunct treatments for DME have been studied, and various pharmacological compounds are under investigation, such as intravitreal triamcinolone acetonide (IVTA) and therapies using inhibitors of vascular endothelial growth factor (VEGF)\(^4\). Studies performed by DRCR.net demonstrated that despite the early benefits of intravitreal injection of 4 mg of triamcinolone acetonide (TA), the BCVA and retinal thickening at 4 mo compared with a 1-mg TA dose or with focal/grid photocoagulation, the final mean BCVA at 2 and 3 years was better in the MPC group\(^5,15,16\).

VEGF expression and signaling are deregulated in DR, and VEGF is an important mediator of blood retinal barrier breakdown, which leads to fluid leakage below the macula and the development of macular edema. Therefore, at present, treatment with anti-VEGF agents is one of the most promising approaches for the treatment of vision loss due to DME\(^18,19\). Several studies have been conducted that have addressed the efficacy and safety of anti-VEGF agents, including ranibizumab (Lucentis, Genentech, Inc., United States), pegaptanib (Macugen, OSI/Eyetech, United States), and aflibercept (EYLEA; Regeneron, United States) and bevacizumab (Avastin, Genentech, Inc., United States), in the treatment of DME.
It has been shown that pegaptanib inhibits VEGF permeability effects\(^\text{[20,21]}\). The VEGF Inhibition Study in Ocular Neovascularization trial established the safety and efficacy in neovascular age-related macular disease (AMD)\(^\text{[22]}\). For DME, the efficacy and safety of 0.3 mg of pegaptanib sodium \(\times 5\) sham injections was studied in a phase-2/3, multicenter, randomized, double-blinded trial\(^\text{[23]}\). After 102 wk, the pegaptanib group presented significantly better results than the sham injection group in BCVA change, letters gained and reduced need for focal/grid laser photocoagulation.

Recently, 2 mg/0.05 mL aflibercept (EYLEA; Regeneron, United States) received regulatory approval from the Food and Drug Administration (FDA) for the treatment of neovascular AMD. For management of DME, a multicenter, randomized, double-masked, phase-2 clinical trial, the DA VINCI Study, tested different dosing regimens of aflibercept (VEGF Trap-Eye) and compared them with laser photocoagulation: 0.5 mg every 4 wk, 2 mg every 4 wk, 2 mg for the 3 initial doses then every 8 wk, 2 mg for the 3 initial doses then as needed. Subjects in the VEGF Trap-Eye groups experienced mean reductions in central retina thickness and, at their 6-mo follow-up, had better results for BCVA than those who were treated with laser photocoagulation. However, it is important to note that a considerable number of re-injections were necessary.

The drug was well tolerated. The phase-3 trials on aflibercept in patients with visual loss due to DME are ongoing\(^\text{[24,25]}\).

Ranibizumab is approved for the treatment of neovascular AMD and just received FDA approval (August 2012) for the treatment of visual impairment due to DME, based on the RIDE and RISE clinical trials. Several clinical trials have been performed examining the use of ranibizumab for the treatment of visual impairment due to DME. The RESTORE study demonstrated superiority after 12 mo of ranibizumab monotherapy (0.5 mg) administered as needed or as an adjunct to laser photocoagulation \(\times 5\) laser photocoagulation\(^\text{[26,27]}\). The READ-2 study found that ranibizumab (0.5 mg) alone or in combination with laser photocoagulation improved BCVA over 2 years in DME patients\(^\text{[28]}\). RIDE and RISE, two identically-designed, parallel, double-blinded, 3-year clinical trials that were sham-treatment controlled for 24 mo had preliminary results that demonstrated that patients who received 0.3 mg of ranibizumab experienced significant, early and sustained improvements in vision. The DRCR.net conducted a study to investigate the role of ranibizumab and also steroid treatment combined with laser photocoagulation. The 2-year results of this study indicated that 0.5 mg of ranibizumab administered as needed and combined with laser therapy produced a rapid and sustained improvement in the BCVA of patients with DME compared with laser treatment\(^\text{[29]}\).

**BEVACIZUMAB FOR DME**

Bevacizumab is a full-size, humanized, recombinant monoclonal immunoglobulin G antibody that inactivates all VEGF isoforms. It is approved as an anti-VEGF agent for the systemic treatment of metastatic colorectal cancer, but its use for ocular diseases is off-label. Intravitreal bevacizumab (IVB) has been more widely utilized, primarily due to its low cost, safety and positive clinical effects in case studies and retrospective studies (Figure 4)\(^\text{[29-31]}\). The widespread use of IVB for the exudative form of AMD as well as the evidence of positive clinical effects in the management of DME\(^\text{[28,32,33]}\) have resulted in the formal evaluation of its safety and efficacy in the management of DME\(^\text{[34]}\).

**RESULTS AND DISCUSSION**

The DRCR.net conducted a randomized study of 121 eyes over a 12-wk period\(^\text{[35]}\). It consisted of five treatment arms: (1) focal photocoagulation; (2) two intravitreal injections of 1.25 mg of bevacizumab at 0 and 6 wk; (3) two intravitreal injections of 2.5 mg of bevacizumab at 0 and 6 wk; (4) 1.25 mg of bevacizumab at week 0 followed by a sham injection at 6 wk; and (5) 1.25 mg of bevacizumab at 0 and 6 wk combined with focal photocoagula-
tion at 3 wk. The majority of eyes, 69%, were refractory to previous treatment for DME. The eyes of two groups that received two bevacizumab injections without laser, 2 and 3, had a significant BCVA improvement over the laser-only group 1, and this difference persisted through the 12 wk. These two groups also had a greater improvement in central subfield thickness at the 3-wk visit. No differences were observed between groups 2 and 3 (1.25-mg and 2.5-mg doses, respectively). The single injection group had no advantage over the photoocoagulation group in this study. Group 5, which combined bevacizumab with photoocoagulation, had results comparable with laser-only treatment. This study suggested that bevacizumab was an effective drug for the management of DME as a primary treatment and also for refractory eyes. Safety data were reported for 24 wk, and no safety concerns were detected. Two trends were identified: (1) the eyes that received primary treatment had greater improvement (P = 0.04) than the refractories; and (2) the presence of subretinal fluid at the initial therapy [measured by optical coherence tomography (OCT)] may be associated with a greater improvement in BCVA (P = 0.06).

The DRCR.net study identified no difference between 1.25 mg and 2.5 mg of bevacizumab, and similar outcomes have been previously reported by other colleagues in retrospectively designed studies[35,36]. One of these studies involved three initial injections monthly and a follow-up period of 6 mo[37]; another study followed the same design but with a 12-mo follow-up[38]. Both studies demonstrated significant reductions in central foveal thickness (CFT) by OCT evaluation and also significant improvements in BCVA[33,34]. There were statistically similar outcomes for the two study groups throughout the 6 initial months and a trend toward recurrence of edema at the 1-year follow-up, suggesting a trend of reducing the CFT during the 2-3 mo following the intravitreal bevacizumab injection (IVBI)[39].

Another study focused on IVB for DME investigated a remarkably diverse group of eyes, with no exclusions based on previous treatment, ischemia, or poor initial BCVA[40]. The study consisted of a noncomparative trial of 1.25 mg of bevacizumab at baseline, with subsequent re-treatment based on improvement in OCT or BCVA response to the initial injection. At 6 mo, there was no significant improvement in mean BCVA, but there were significant decreases in the mean CFT according to OCT evaluation. Although some characteristics of this study led to difficulty in analyzing its results, such as the diverse baseline data and a variable number of treatments, the results corroborated the idea that bevacizumab should be the object of further studies for eyes with DME refractory to previous treatments, as this therapeutic approach was able to decrease the CFT as measured by OCT.

When investigating the long-term effects of intravitreal bevacizumab in patients with chronic diffuse DME, Kook et al[41] observed a decrease in central macular thickness (CMT) and again in BCVA following repeated intravitreal injections of bevacizumab, even in cases with chronic diffuse ischemic DME.

Bonini-Filho et al[42] performed a pilot study of IVB-treatment for macular edema in ten eyes with severe-capillary loss. The treatment used 1.5-mg dosing, and all ten eyes underwent an injection at baseline. Re-treatment at follow-up visits was based on the presence of intraretinal or subretinal fluid on OCT. After 54 wk, the CMT and BCVA improved significantly. No progression of capillary loss was observed in fluorescein angiogram at the end of the study.

The BOLT Study, a prospective, randomized, blinded, single-center study, compared IVB and macular laser photocoagulation in patients with persistent CSME after at least one macular laser treatment[43]. Eighty eyes were randomized into a bevacizumab treatment group (with injections every 6 wk), with a minimum of 3 and a maximum of 9 injections, or a photocoagulation group, with sessions every 4 mo and a minimum of 1 and a maximum of 4 treatments. After 1 yr, the mean BCVA measured by ETDRS evaluation increased in the bevacizumab group and deteriorated in the laser group. The CMT results were also favorable for the bevacizumab group. The median number of injections in this first year was 9 in the bevacizumab group, and the median number of laser treatments was 3.

The 2-year outcome report of the BOLT Study was published recently and presented similar results to the first year report[44]. The mean ETDRS equivalent Snellen was 20/50 in the bevacizumab group and 20/80 in the laser group (P = 0.005). The bevacizumab group gained a median of 9 ETDRS letters vs 2.5 letters for the laser treatment group (P = 0.005), with a mean gain of 8.6 letters for bevacizumab vs a mean gain of 0.5 letters for the laser group. Among the eyes treated with bevacizumab, 32% gained at least 15 letters vs 4% for the laser-treated eyes (P = 0.004). The percentage of patient eyes that lost fewer than 15 letters in the macular laser treatment group was 86% vs 100% for the bevacizumab group (P = 0.03). At 2 yrs, the CMT decreased significantly in both groups. At the 2-year follow-up, the median number of injections was 13, and the median number of laser treatments was 4.

In addition to MPC, some of the largest trials published examining bevacizumab use for DME have compared intravitreal bevacizumab and intravitreal triamcinolone (IVT).

Ahmadieh et al[45] conducted a 24-wk trial randomizing 115 eyes to one of three study arms: a bevacizumab-only arm, an IVTA/bevacizumab combination arm, and a placebo arm. The two treatment arms received three 1.25-mg bevacizumab injections every 6 wk, and the IVTA/bevacizumab group received an additional injection of 2 mg of triamcinolone at the baseline visit only. No difference in BCVA or CMT was detected between the bevacizumab and IVTA/bevacizumab groups.

In a study performed by Faghhi et al[46], IVB-only was compared with bevacizumab associated to triamcinolone and with MPC in eyes with no history of treatment.
Dosings of 1.25 mg of bevacizumab and 2 mg of triamcinolone were used, and injections were performed at the baseline visit only. The three groups had significant improvements in CMT at both the 6- and 16-wk visits vs baseline. A similar trend was observed for BCVA; the bevacizumab group outperformed the laser group in CMT and BCVA at 6 wk but not at 16 wk. The bevacizumab/IVTA group outperformed the laser group in CMT and BCVA at both 6 and 16 wk.

A randomized clinical trial comparing IVB injection alone or in combination with IVTA as macular laser photoagulation as a primary treatment for DME was conducted by Soheilian et al[5,43], and the 2-year outcomes results were recently published. In total, 150 eyes were randomly assigned to 1 of the 3 study arms: the 1.25-mg IVB group; the IVB/IVT group, with 1.25 mg of IVB and 2 mg of IVT; and the macular laser group. There was significant superiority of visual acuity improvement in the IVB group after 6 mo, but this was not sustained after 24 mo. The mean BCVA improvement was greater in the IVB group than in the other groups and also in the IVB/IVT group compared with the laser group. The same was noted for the reduction of CMT, which was more evident in the IVB group compared to the other groups. However, the difference among the groups was not significant, which may be related to some methodological aspects, such as the 3-mo re-treatment intervals, when indicated, or the missing data in 24.6% of the cases at the final follow-up.

In a retrospective study, Wu et al[44] aimed to identify OCT patterns in diabetic DME that were predictive of visual outcomes after IVBIs. Thirty-one eyes with clinically significant DME[33] and without previous treatment underwent complete ophthalmic examination and OCT. The eyes were classified into 4 groups, based on the cross-sectional retinal morphologies, by using OCT features: diffuse retinal thickening, cystoid macular edema (CME), serous retinal detachment and vitreomacular interface abnormalities. The minimum required follow-up was 3 mo. Changes in CMT and total macular volume after IVB injections were evaluated as well as the BCVA. Patients with CME exhibited greater improvement in all evaluated parameters compared with other groups. The study concluded that OCT patterns in DME may be helpful in deciding the best treatment and predicting the outcome after IVBI. In addition, the study indicates that IVBI could be a primary therapeutic modality for CME[34]. Similar results were found in a retrospective study conducted by Roh et al[39].

The Pan-American Collaborative Retina Study Group has published the 24-mo results of a study examining intravitreal bevacizumab as the primary treatment for diffuse DME (DDME). For these retrospective, multicenter, interventional, comparative case series, the clinical data of 139 eyes with DDME at 11 centers from 8 countries were reviewed. All of the eyes were treated with off-label IVB with at least 1 intravitreal injection of 1.25 or 2.5 mg of bevacizumab. The dose received at baseline was the same dose delivered throughout the study. The exclusion criteria were as follows: patients with DDME that were treated with laser photoagulation or intravitreal triamcinolone previously, macular ischemia, intraocular inflammation, a prior history of vitreoretinal surgery or cataract surgery within the past 6 mo, uncontrolled intraocular pressure, and the presence of an epiretinal membrane or vitreomacular traction syndrome. Each patient underwent BCVA measurement with ETDRS charts, ophthalmic examination and OCT at baseline and 1, 3, 6, 12 and 24 mo after the initial injection. Fluorescein angiography was performed at the discretion of the examiner (usually every 6 mo). Patients received re-injections whenever there was a recurrence of DDME.

One month after the initial bevacizumab injection, improvements in the BCVA and CMT measurements were observed, and these significant changes continued during the 24-mo follow-up period. The improvement of the BCVA and OCT from one study after 6 injections during the 2-year period is shown (Figure 5). BCVA analysis demonstrated that after 24 mo, 72 (51.8%) eyes improved 2 or more ETDRS lines, 62 (44.6%) eyes remained stable, and 5 (3.6%) eyes decreased 2 or more ETDRS lines of BCVA. A twenty-four-month OCT analysis indicated that CMT measurements decreased from 446.4 ± 154.4 µm to 279.7 ± 80 µm. The mean number of IVB injections per eye was 5.8 (range, 1-15 injections) at a mean interval of 12.2 ± 10.4 wk. The data analysis of BCVA and CMT found no significant differences between the 1.25- and 2.5-mg dose groups[39].

A systematic review of IVBI for the treatment of primary DME was conducted by Yilmaz et al[46] and published in 2011. The review compared IVB injection vs MPC vs a combination IVB/IVTA injection in improving the BCVA of patients without previous treatment for
DME. The review included four randomized clinical trials comparing IVB injection with macular laser and three of them also comparing IVB injection with IVB/IVTA. The outcomes indicated that IVB injection is effective in improving BCVA in primary DME; for 6 wk, but the benefits are no longer present at 12 wk after injection. IVTA had no detectable adjunctive effect.

Throughout the discussion of this systematic review, various limitations may be responsible for these observed outcomes, which somewhat contradict the trends shown in previous studies. First, this review was limited to four randomized controlled trials, and all of them had varied baseline characteristics. The DRCR.net study provided BCVA and CMT values that were not estimable in our analysis because there was a mixture of patients with and without prior treatment for DME. However, that study was included in the systematic review to emphasize that patients from IVB groups did improve in their BCVA and CMT values compared to the laser group. Another relevant aspect is that a decrease in efficiency may be related to the cessation of treatment in those studies in which just one injection was performed. The DRCR.net demonstrated that the improvement results were sustained for 12 wk with two IVB injections.

Therefore, the limitations of this analysis may corroborate the idea that IVB is effective in treating primary DME; however, IVB should not be considered the first line of treatment.

The safety of the intravitreal use of bevacizumab has also been studied. A retrospective study involving 1173 patients who received intravitreal bevacizumab and were followed for 12 mo is likely the largest series regarding the use of bevacizumab in DME. In this study, the following adverse effects were observed: seven cases of acute elevation of blood pressure, six strokes, five myocardial infarctions, five deaths, seven cases of bacterial endophthalmitis, seven cases of tractional retinal detachment (TRD), and four cases of uveitis. These numbers were similar to those found in the prospective, controlled studies of the other anti-VEGF agents.

TRD in proliferative diabetic retinopathy following intravitreal bevacizumab may happen because of natural history or rapid neovascular involution with accelerated fibrosis and posterior hyaloidal contraction as a response to decreased levels of VEGF. Arevalo et al., in a retrospective review, identified a 5.2% incidence of development or progression of TRD after treatment with intravitreal bevacizumab. Therefore, treatment with bevacizumab for patients with proliferative DR and DME must be cautiously applied, especially in cases with elevated glycosylated hemoglobin, patients with type 1 diabetes with poor glycemic control, patients without previous PRP or refractory to this treatment and the presence of areas of isolated TRD.

Although delivered intravitreally, anti-VEGF drugs can potentially circulate systemically. Systemic side-effects such as arterial thromboembolism, gastrointestinal perforation, hemorrhage, hypertensive crisis, and nephrotic syndrome are the main safety concerns surrounding the use of intravenous bevacizumab in patients with a diagnosis of colorectal cancer and other important systemic comorbidities.

CONCLUSION

There is growing evidence that IVBI is safe and effective for the treatment of DME, both for cases with no prior treatment as well as for refractory eyes. The rationale of the current trend of using a combination therapy of IVBI with laser photocoagulation is based on the fast recovery of macular anatomy/BCVA related to prompt VEGF inhibition (due to the IVBI) associated with the long-term effects of laser (that may decrease the necessity of IVBI due to the sustained anti-VEGF effects of laser scars).

Comparing the effects of bevacizumab and other VEGF inhibitors is difficult; however, the cost-effectiveness and safety of IVB is certainly the most important benefit of such treatment in comparison to all commercially available anti-VEGF therapies.

To optimize the management of DME, more studies should be performed to confirm its effectiveness and the duration of its benefits and to establish guidelines for the mean number and periodicity of IVBIs, either in isolation or combined with laser photocoagulation.

ACKNOWLEDGMENTS

We would like to thank the Fundação de Amparo à Pesquisa do Estado de São Paulo and Conselho Nacional de Pesquisa.

REFERENCES

1. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007; 14: 179-183 [PMID: 17986294 DOI: 10.1080/09286580701396720]
2. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol 2012; 96: 614-618 [PMID: 22133988 DOI: 10.1136/bjophthalmol-2011-300539]
3. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248: 915-930 [PMID: 20174816 DOI: 10.1007/s00417-010-1315-z]
4. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 1984; 91: 1-9 [PMID: 6709312]
5. Soheilian M, Garfami KH, Ramezani A, Yaseri M, Peyman GA. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina 2012; 32: 314-321 [PMID: 22234244 DOI: 10.1097/IAE.0b013e3182f55de]
6. Lang GE, Lang SJ. [Clinical treatment of diabetic macular edema]. Klin Monbl Augenheilkd 2011; 228: R1-11; quiz R12-13 [PMID: 21249607]
7. Lang GE. Diabetic macular edema. Ophthalmologica Journal international d’ophthalmologie. Int J Ophthalmol 2012; 227 Suppl 1: 21-29
8. Bernard JA, Guyot-Argenton C, Bennmehidi A, Marielescure C. Hard exudates in diabetic retinopathy. Bull Soc Belge Ophtalmol 1995; 256: 61-64 [PMID: 8381232]
9. Transo PG, Wickremasinghe SS, Stanos NT, Topouzis F,
Tsinopoulos I, Pavcescu CE. Macular edema. Surv Ophthalmol 2004; 49: 470-490 [PMID: 15325193]

10 Lopes de Faria JM, Jalkh AE, Trempe CL, McMeel JW. Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol Scand 1999; 77: 171-175 [PMID: 10321533 DOI: 10.1034/j.1600-0420.1999.770211.x]

11 Royle P, Cummins E, Henderson R, Lois N, Shyamandan D, Waugh N. Ranibizumab for the Treatment of Diabetic Macular Oedema: a single technology appraisal. Aberdeen: Aberdeen Health Technology Assessment Group, 2011

12 Klein R, Klein BE, Moss SR, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1999; 105: 1801-1815 [PMID: 9787347 DOI: 10.1016/S0161-6420(98)91020-X]

13 Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796-1806 [PMID: 2866795 DOI: 10.1001/archopht.1985.01050120030015]

14 Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98: 766-785 [PMID: 2062512]

15 Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077.e35 [PMID: 20420788]

16 Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447-1449, 1449.e1-10 [PMID: 18662829]

17 Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hattnett E, Ip MS, Kim JE, Kollman C. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127: 245-251 [PMID: 19273785 DOI: 10.1001/archophthalmol.2008.610]

18 Caldwell RB, Bartoli M, Behzadzian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, Caldwell RW. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003; 19: 442-455 [PMID: 14648803 DOI: 10.1002/dmr.415]

19 Simó R, Hernández C. Intravitreal anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 2008; 51: 1574-1580 [PMID: 18404258]

20 Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmad E, Carraquillo KG, Amano S, Hida T, Oguchi Y, Adamis AP. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003; 44: 2155-2162 [PMID: 12714656 DOI: 10.1167/iovs.02-00870]

21 Bell C, Lynam E, Landfair DJ, Janjic N, Wiles ME. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim 1999; 35: 533-542 [PMID: 10548435 DOI: 10.1007/s11262-999-0064-y]

22 Gragoudas ES, Adams AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816 [PMID: 15625332 DOI: 10.1056/NEJMoa042760]

23 Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011; 118: 1107-1118 [PMID: 21529957 DOI: 10.1016/j.ophtha.2011.02.045]

24 Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, To-
Stefanini FR et al. Bevacizumab for the management of diabetic macular edema

1034-x

36 Lam DS, Lai TY, Lee VY, Chan CK, Liu DT, Mohamed S, Li CL. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina 2009; 29: 292-299 [PMID: 19287286 DOI: 10.1097/IAE.0b013e31819a2d61]

37 Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005 [PMID: 17151486 DOI: 10.1097/01.iae.0000247165.38655.bf]

38 Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, Kampik A, Haritoglou C. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008; 28: 1053-1060 [PMID: 18779710 DOI: 10.1097/IAE.0b013e318176de48]

39 Bonini-Filho M, Costa RA, Calucci D, Jorge R, Melo LA, Scott IU. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study. Am J Ophthalmol 2009; 147: 1022-1030, 1030.e1-5 [PMID: 19327746]

40 Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, Boos CJ, Xing W, Egan C, Peto T, Bunce C, Leslie RD, Hykin PG. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010; 117: 1078-1086.e2 [PMID: 20416952]

41 Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Espositi SD, Peto T, Egan C, Bunce C, Leslie RD, Hykin PG. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012; 130: 972-979 [PMID: 22491395]

42 Faghihi H, Roohipoor R, Mohammad SF, Hojat-Jalali K, Mirshahi A, Lashay A, Piri N, Faghihi Sh. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photoacoagulation in diabetic macular edema. Eur J Ophthalmol 2008; 18: 941-948 [PMID: 18988166]

43 Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, Ahmadieh H, Dehghan MH, Azarmina M, Moradian S, Peyman GA. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmolog 2009; 116: 1142-1150 [PMID: 19376585 DOI: 10.1016/j.ophtha.2009.01.011]

44 Wu PC, Lai CH, Chen CL, Kuo CN. Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment. J Ocul Pharmacol Ther 2012; 28: 59-64 [PMID: 21992557 DOI: 10.1089/jop.2011.0070]

45 Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini AA, Brito M, Bonafonte S, Lujan S, Diaz-Llopis M, Restrepo N, Rodriguez FJ, Udaondo-Mirete P. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 2009; 116: 1488-1497, 1497.e1 [PMID: 19545900]

46 Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246: 81-87 [PMID: 17674014 DOI: 10.1007/s00417-007-0660-z]

47 Arevalo JF, Maia M, Flynn HW, Saravia M, Avery RL, Wu L, Eid Farah M, Pieramici DJ, Berrocal MH, Sanchez JG. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92: 213-216 [PMID: 17965108 DOI: 10.1136/bjo.2007.127142]

P- Reviewer Simo R S- Editor Wen LL L- Editor A E- Editor Li JY